KEYNOTE-365 cohort B updated results: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza) pre-treated patients with metastatic castration-resistant prostate cancer (mCRPC)

Bibliographic Details
Main Authors:	G. Gravis, M. Kolinsky, L. Mourey, J.M. Piulats, S. Sridhar, E. Romano, W. Berry, H. Gurney, M. Retz, L. Appleman, M. Boegemann, J. De Bono, A. Joshua, U. Emmenegger, H. Conter, B. Laguerre, H. Wu, C. Schloss, C. Poehlein, E.Y. Yu
Format:	Article
Language:	English
Published:	Elsevier 2020-07-01
Series:	European Urology Open Science
Online Access:	http://www.sciencedirect.com/science/article/pii/S2666168320331633

id	doaj-714426087a914766a3f6599eaa157ff7
record_format	Article
spelling	doaj-714426087a914766a3f6599eaa157ff72020-12-30T04:15:48ZengElsevierEuropean Urology Open Science2666-16832020-07-0119e871e872KEYNOTE-365 cohort B updated results: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza) pre-treated patients with metastatic castration-resistant prostate cancer (mCRPC)G. GravisM. KolinskyL. MoureyJ.M. PiulatsS. SridharE. RomanoW. BerryH. GurneyM. RetzL. ApplemanM. BoegemannJ. De BonoA. JoshuaU. EmmeneggerH. ConterB. LaguerreH. WuC. SchlossC. PoehleinE.Y. Yuhttp://www.sciencedirect.com/science/article/pii/S2666168320331633
collection	DOAJ
language	English
format	Article
sources	DOAJ
author	G. Gravis M. Kolinsky L. Mourey J.M. Piulats S. Sridhar E. Romano W. Berry H. Gurney M. Retz L. Appleman M. Boegemann J. De Bono A. Joshua U. Emmenegger H. Conter B. Laguerre H. Wu C. Schloss C. Poehlein E.Y. Yu
spellingShingle	G. Gravis M. Kolinsky L. Mourey J.M. Piulats S. Sridhar E. Romano W. Berry H. Gurney M. Retz L. Appleman M. Boegemann J. De Bono A. Joshua U. Emmenegger H. Conter B. Laguerre H. Wu C. Schloss C. Poehlein E.Y. Yu KEYNOTE-365 cohort B updated results: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza) pre-treated patients with metastatic castration-resistant prostate cancer (mCRPC) European Urology Open Science
author_facet	G. Gravis M. Kolinsky L. Mourey J.M. Piulats S. Sridhar E. Romano W. Berry H. Gurney M. Retz L. Appleman M. Boegemann J. De Bono A. Joshua U. Emmenegger H. Conter B. Laguerre H. Wu C. Schloss C. Poehlein E.Y. Yu
author_sort	G. Gravis
title	KEYNOTE-365 cohort B updated results: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza) pre-treated patients with metastatic castration-resistant prostate cancer (mCRPC)
title_short	KEYNOTE-365 cohort B updated results: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza) pre-treated patients with metastatic castration-resistant prostate cancer (mCRPC)
title_full	KEYNOTE-365 cohort B updated results: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza) pre-treated patients with metastatic castration-resistant prostate cancer (mCRPC)
title_fullStr	KEYNOTE-365 cohort B updated results: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza) pre-treated patients with metastatic castration-resistant prostate cancer (mCRPC)
title_full_unstemmed	KEYNOTE-365 cohort B updated results: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza) pre-treated patients with metastatic castration-resistant prostate cancer (mCRPC)
title_sort	keynote-365 cohort b updated results: pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza) pre-treated patients with metastatic castration-resistant prostate cancer (mcrpc)
publisher	Elsevier
series	European Urology Open Science
issn	2666-1683
publishDate	2020-07-01
url	http://www.sciencedirect.com/science/article/pii/S2666168320331633
work_keys_str_mv	AT ggravis keynote365cohortbupdatedresultspembrolizumabpembroplusdocetaxelandprednisoneinabirateroneabiorenzalutamideenzapretreatedpatientswithmetastaticcastrationresistantprostatecancermcrpc AT mkolinsky keynote365cohortbupdatedresultspembrolizumabpembroplusdocetaxelandprednisoneinabirateroneabiorenzalutamideenzapretreatedpatientswithmetastaticcastrationresistantprostatecancermcrpc AT lmourey keynote365cohortbupdatedresultspembrolizumabpembroplusdocetaxelandprednisoneinabirateroneabiorenzalutamideenzapretreatedpatientswithmetastaticcastrationresistantprostatecancermcrpc AT jmpiulats keynote365cohortbupdatedresultspembrolizumabpembroplusdocetaxelandprednisoneinabirateroneabiorenzalutamideenzapretreatedpatientswithmetastaticcastrationresistantprostatecancermcrpc AT ssridhar keynote365cohortbupdatedresultspembrolizumabpembroplusdocetaxelandprednisoneinabirateroneabiorenzalutamideenzapretreatedpatientswithmetastaticcastrationresistantprostatecancermcrpc AT eromano keynote365cohortbupdatedresultspembrolizumabpembroplusdocetaxelandprednisoneinabirateroneabiorenzalutamideenzapretreatedpatientswithmetastaticcastrationresistantprostatecancermcrpc AT wberry keynote365cohortbupdatedresultspembrolizumabpembroplusdocetaxelandprednisoneinabirateroneabiorenzalutamideenzapretreatedpatientswithmetastaticcastrationresistantprostatecancermcrpc AT hgurney keynote365cohortbupdatedresultspembrolizumabpembroplusdocetaxelandprednisoneinabirateroneabiorenzalutamideenzapretreatedpatientswithmetastaticcastrationresistantprostatecancermcrpc AT mretz keynote365cohortbupdatedresultspembrolizumabpembroplusdocetaxelandprednisoneinabirateroneabiorenzalutamideenzapretreatedpatientswithmetastaticcastrationresistantprostatecancermcrpc AT lappleman keynote365cohortbupdatedresultspembrolizumabpembroplusdocetaxelandprednisoneinabirateroneabiorenzalutamideenzapretreatedpatientswithmetastaticcastrationresistantprostatecancermcrpc AT mboegemann keynote365cohortbupdatedresultspembrolizumabpembroplusdocetaxelandprednisoneinabirateroneabiorenzalutamideenzapretreatedpatientswithmetastaticcastrationresistantprostatecancermcrpc AT jdebono keynote365cohortbupdatedresultspembrolizumabpembroplusdocetaxelandprednisoneinabirateroneabiorenzalutamideenzapretreatedpatientswithmetastaticcastrationresistantprostatecancermcrpc AT ajoshua keynote365cohortbupdatedresultspembrolizumabpembroplusdocetaxelandprednisoneinabirateroneabiorenzalutamideenzapretreatedpatientswithmetastaticcastrationresistantprostatecancermcrpc AT uemmenegger keynote365cohortbupdatedresultspembrolizumabpembroplusdocetaxelandprednisoneinabirateroneabiorenzalutamideenzapretreatedpatientswithmetastaticcastrationresistantprostatecancermcrpc AT hconter keynote365cohortbupdatedresultspembrolizumabpembroplusdocetaxelandprednisoneinabirateroneabiorenzalutamideenzapretreatedpatientswithmetastaticcastrationresistantprostatecancermcrpc AT blaguerre keynote365cohortbupdatedresultspembrolizumabpembroplusdocetaxelandprednisoneinabirateroneabiorenzalutamideenzapretreatedpatientswithmetastaticcastrationresistantprostatecancermcrpc AT hwu keynote365cohortbupdatedresultspembrolizumabpembroplusdocetaxelandprednisoneinabirateroneabiorenzalutamideenzapretreatedpatientswithmetastaticcastrationresistantprostatecancermcrpc AT cschloss keynote365cohortbupdatedresultspembrolizumabpembroplusdocetaxelandprednisoneinabirateroneabiorenzalutamideenzapretreatedpatientswithmetastaticcastrationresistantprostatecancermcrpc AT cpoehlein keynote365cohortbupdatedresultspembrolizumabpembroplusdocetaxelandprednisoneinabirateroneabiorenzalutamideenzapretreatedpatientswithmetastaticcastrationresistantprostatecancermcrpc AT eyyu keynote365cohortbupdatedresultspembrolizumabpembroplusdocetaxelandprednisoneinabirateroneabiorenzalutamideenzapretreatedpatientswithmetastaticcastrationresistantprostatecancermcrpc
_version_	1724366861921943552

KEYNOTE-365 cohort B updated results: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza) pre-treated patients with metastatic castration-resistant prostate cancer (mCRPC)

Similar Items